Notice From the Securities Law Firm of Klayman & Toskes to All Securities America, CapWest Securities and Cullum & Burks Securit
September 30 2009 - 4:45PM
Marketwired
The Securities Law Firm of Klayman & Toskes, P.A. ("K&T"),
www.nasd-law.com, announced today that a class action lawsuit, Case
No. 8:09-cv-01084, has been filed against Ameriprise Financial
(NYSE: AMP) and its broker-dealer subsidiary Securities America, as
well as Cullum & Burks Securities and CapWest Securities, on
behalf of investors who purchased or otherwise acquired notes of
Medical Provider Financial Corp. III, Medical Provider Financial
Corp. IV, Medical Provider Funding Corp. V and Medical Provider
Funding Corp. VI (collectively referred to as "Medical Capital
notes") from Securities America, CapWest Securities and/or Cullum
& Burks. Potential class members who purchased Medical Capital
notes from Securities America, CapWest Securities or Cullum &
Burks should consider whether they should participate in the class
action or file an individual securities arbitration claim.
The Complaint alleges that "Cullum & Burks, Securities
America, CapWest Securities and their affiliates did not make a
reasonable investigation or possess reasonable grounds to believe
that the statements contained and incorporated by reference in the
[Private Placement Memoranda] at the time of the MedCap Entities'
offerings were true and without omissions of material fact and were
not misleading. Had Defendants Cullum & Burks, Securities
America, CapWest Securities and their affiliates exercised
reasonable care, they would have known of such omissions." Under
NASD Rules, brokerage firms have an obligation to make suitable
recommendations to their customers and to conduct adequate due
diligence of new products before they are sold to their
customers.
FINRA has provided guidance concerning the kinds of questions
which should be asked by a brokerage firm before offering a new
product, and it has highlighted best practices for reviewing new
products. Specifically, FINRA has stressed the need for firms to
take a proactive approach in reviewing and improving their
procedures for developing and vetting new products. Those
procedures should include straightforward guidelines for
determining what constitutes a new product, ensure that the proper
questions are asked and answered before a new product is offered
for sale, and provide for post-approval follow-up and review.
K&T reminds investors of the benefits of filing an
individual securities arbitration claim, as opposed to
participating in a class action lawsuit. By participating in a
class action lawsuit, an investor will most likely recover only
pennies on the dollar. However, if one has experienced significant
losses in Medical Capital notes, it may be more beneficial for them
to file an individual securities arbitration claim. In 2003,
K&T conducted a detailed study of securities arbitration versus
class action. The study concluded that investors who file a
securities arbitration claim traditionally obtain an overall higher
rate of recovery as opposed to participating in a class action
lawsuit. To view the full results of the comparison, please visit
our web-site: http://www.nasd-law.com/documents/classvr.pdf
Retail and institutional investors who purchased Medical Capital
notes from a full-service brokerage firm and sustained significant
losses can contact K&T to explore their legal rights and
options. The attorneys at K&T are dedicated to pursuing claims
on behalf of investors who have suffered investment losses.
K&T, an experienced, qualified and nationally recognized
securities litigation law firm, practices exclusively in the field
of securities arbitration and litigation. It continues its
representation of investors throughout the world in securities
arbitration and litigation matters against major Wall Street
brokerage firms.
If you wish to discuss this announcement or have investment
losses of $200,000 or more in Medical Capital notes, please contact
Steven D. Toskes, Esquire or Jahan K. Manasseh, Esquire of Klayman
& Toskes, P.A., at 888-997-9956, or visit us on the web at
http://www.nasd-law.com.
Contact Steven D. Toskes, Esquire Jahan K. Manasseh, Esquire
Klayman & Toskes, P.A. 888-997-9956 http://www.nasd-law.com
Ameriprise Financial (NYSE:AMP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ameriprise Financial (NYSE:AMP)
Historical Stock Chart
From Jul 2023 to Jul 2024